Indian consumers are lapping up Chinese phones at a furious pace. Many models get sold out within seconds of a sale being announced on either Amazon or Flipkart.
#MintPlainFacts | After languishing in the bottom half of Mint’s emerging markets tracker over the past few months, India has now moved to the third position among the 10 largest emerging markets, outranking Asian peers
In May and June, as India struggled to contain the second wave, several Asian peers experienced a robust economic recovery on the back of a rebound in global trade.
The key differentiator for India remains a low covid case count. It is the decline in caseloads & the opening up of the economy that have allowed manufacturing activity to roar back to life...
#MintPlainFacts | The government presents a mixed card in the first quarter on the two cornerstones of its fiscal strategy. On revenue collection, it exceeded expectations. On capital expenditure, it’s below expectations
The Union government is off to its best revenue collection drive in five years, with collections touching 28% of its budgeted revenues for fiscal year 2021-22 (FY22) in the first quarter (April-June) alone.
The Centre has done well in receipts, but not on capital spending. On 30 June, the Centre directed ministries, with some exceptions, to limit their spending in the second quarter to 20% of the full-year amount
#MintLongStory | India can draw lessons from the turnaround models of other nations. For instance, UK Sport, which spent about ₹1,500 crore in 2019-20, was set up to increase UK’s Olympic medal count
#MintPlainFacts | The online survey, which covered 10,285 respondents across 203 cities in the June-July period, shows that 41% respondents find the Prime Minister (PM) responsible for the covid tragedy.
The continued support for incumbents in the face of disaster may appear baffling at first. However, there are three important clues in the survey that help us make sense of this reaction.
#MintLongStory | The detection of carcinogenic compounds in commonly used drugs has plunged the global pharma industry into crisis mode. India’s drug regulator has done little to protect citizens
The suspension of ranitidine sales in multiple countries, which happened in 2020, is just one part of a much bigger crisis that has engulfed the global pharmaceutical industry.
The crisis first crept up in June 2018, when the European drug regulator, the EMA, learnt that batches of a drug used to treat high blood pressure, called valsartan, had dangerously high levels of NDMA.